Brand Name | Status | Last Update |
---|---|---|
enhertu | Biologic Licensing Application | 2025-01-28 |
herceptin | Biologic Licensing Application | 2024-11-18 |
herceptin hylecta | Biologic Licensing Application | 2024-11-21 |
hercessi | Biologic Licensing Application | 2025-03-21 |
herzuma | Biologic Licensing Application | 2025-02-12 |
kadcyla | Biologic Licensing Application | 2024-11-18 |
kanjinti | Biologic Licensing Application | 2024-12-20 |
ogivri | Biologic Licensing Application | 2024-11-30 |
ontruzant | Biologic Licensing Application | 2025-03-11 |
ontruzant ontruzant | Biologic Licensing Application | 2024-03-01 |
Expiration | Code | ||
---|---|---|---|
trastuzumab, Herceptin, Genentech, Inc. | |||
2117-10-20 | Orphan excl. |
Code | Description |
---|---|
J9316 | Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg |
J9354 | Injection, ado-trastuzumab emtansine, 1 mg |
J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg |
J9356 | Injection, trastuzumab, 10 mg and hyaluronidase-oysk |
J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg |
Q5112 | Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg |
Q5113 | Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg |
Q5114 | Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg |
Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg |
Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 247 | 607 | 208 | 18 | 189 | 1152 |
Neoplasms | D009369 | — | C80 | 86 | 74 | 10 | 3 | 26 | 176 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 30 | 71 | 17 | 2 | 16 | 118 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 25 | 43 | 10 | 1 | 8 | 79 |
Cardiotoxicity | D066126 | EFO_1001482 | — | 1 | 6 | 6 | 1 | 24 | 37 |
Male breast neoplasms | D018567 | — | — | 11 | 20 | 2 | 1 | 4 | 34 |
Heart failure | D006333 | EFO_0003144 | I50 | 3 | 4 | — | 1 | 3 | 10 |
Breast diseases | D001941 | — | N60-N65 | 2 | 5 | 2 | 1 | 1 | 9 |
Second primary neoplasms | D016609 | — | — | 1 | 4 | 1 | 1 | 2 | 9 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 3 | 4 | 1 | 1 | — | 8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Adenocarcinoma | D000230 | — | — | 14 | 47 | 12 | — | 9 | 72 |
Carcinoma | D002277 | — | C80.0 | 20 | 31 | 7 | — | 1 | 53 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 10 | 33 | 2 | — | 5 | 46 |
Esophageal neoplasms | D004938 | — | C15 | 13 | 25 | 6 | — | 2 | 39 |
Colorectal neoplasms | D015179 | — | — | 11 | 28 | 3 | — | 2 | 37 |
Non-small-cell lung carcinoma | D002289 | — | — | 12 | 23 | 2 | — | 3 | 35 |
Lung neoplasms | D008175 | — | C34.90 | 14 | 22 | 3 | — | 3 | 35 |
Recurrence | D012008 | — | — | 11 | 12 | 5 | — | 1 | 26 |
Triple negative breast neoplasms | D064726 | — | — | 9 | 16 | 1 | — | — | 23 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 10 | 11 | 2 | — | 1 | 19 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Urologic neoplasms | D014571 | — | C64-C68 | 1 | 9 | — | — | — | 10 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | 3 | 5 | — | — | 1 | 9 |
Transitional cell carcinoma | D002295 | — | — | 2 | 7 | — | — | — | 9 |
Multiple myeloma | D009101 | — | C90.0 | 3 | 5 | — | — | 1 | 8 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 6 | — | — | — | 8 |
Cholangiocarcinoma | D018281 | — | C22.1 | 2 | 7 | — | — | — | 8 |
Squamous cell carcinoma | D002294 | — | — | 3 | 6 | — | — | — | 8 |
Sarcoma | D012509 | — | — | 3 | 5 | — | — | 2 | 8 |
Melanoma | D008545 | — | — | 4 | 6 | — | — | — | 7 |
Left ventricular dysfunction | D018487 | — | — | 1 | 3 | — | — | 3 | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 16 | — | — | — | 2 | 18 |
Hodgkin disease | D006689 | — | C81 | 2 | — | — | — | — | 2 |
Carcinoid tumor | D002276 | — | D3A.00 | 2 | — | — | — | — | 2 |
Ependymoma | D004806 | — | — | 2 | — | — | — | — | 2 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 5 | 5 |
Intestinal diseases | D007410 | — | K63.9 | — | — | — | — | 4 | 4 |
Intestinal polyps | D007417 | EFO_0003855 | — | — | — | — | — | 2 | 2 |
Intestinal obstruction | D007415 | — | K56.60 | — | — | — | — | 2 | 2 |
Drug therapy | D004358 | — | — | — | — | — | — | 2 | 2 |
Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | — | 2 | 2 |
Observation | D019370 | — | — | — | — | — | — | 1 | 1 |
Prospective studies | D011446 | — | — | — | — | — | — | 1 | 1 |
Chemotherapy-related cognitive impairment | D000084202 | — | — | — | — | — | — | 1 | 1 |
Fatigue | D005221 | — | R53.83 | — | — | — | — | 1 | 1 |
Drug common name | Trastuzumab |
INN | trastuzumab |
Description | Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | >5U6A:A|Light Chain
DIQMTQSPILLSASVGDRVTITCRASQDVNTAVAWYQQRTNGSPRLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQP
EDEADYYCQQHYTTPPTFGAGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>5U6A:B|Heavy Chain
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQSPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAY
LQMNSLRAEDTAIYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC |